Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genomic Predictors Associated With Exceptional Response to Systemic Therapy in Advanced Pancreatic Cancer.

Oncology (Williston Park, N.Y.) - 14 Dec 2023

Kamath Suneel, Roopkumar Joanna, Ni Ying, Shen Minqian, Bejarano Pablo, Allende Daniela, Nagarajan Arun, Nguyen Tim, Dergham Bachar, Shepard Dale, Shapiro Marc A, McNamara Michael J, Estfan Bassam N, Nair Kanika G, Khorana Alok A

Abstract excerpt

INTRODUCTION: Exceptional response to therapy is rare in patients with advanced pancreatic cancer. This study explored potential genomic differences between typical and exceptional responses that could confer more favorable biology. METHODS: We included exceptional responders and controls with advanced pancreatic cancer from Cleveland Clinic from April 2013 to August 2017. Exceptional responders were defined as...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to Genomics

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Pancreatic Neoplasms

Share to Progression-Free Survival

Source

Identifiers

PMID: 38133563
DOI: 10.46883/2023.25921008

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genomic Predictors Associated With Exceptional Response to Systemic Therapy in Advanced Pancreatic Cancer.PMID 38133563Read ↗

The Exceptional Responders Initiative: Feasibility of a National Cancer Institute Pilot Study.Semantic proximity Read ↗

What have we learned from exceptional tumour responses?: Review and perspectives.Semantic proximity Read ↗

Rare Germline Variants in Immune and Drug Target Genes Among Cancer Exceptional RespondersSemantic proximity Read ↗

Molecular Profiling of Exceptional Responders to Cancer Therapy.Semantic proximity Read ↗

Molecular Features of Cancers Exhibiting Exceptional Responses to Treatment.Semantic proximity Read ↗

Transforming Biomarker Development with Exceptional Responders.Semantic proximity Read ↗

Clinical and molecular features of early onset pancreatic adenocarcinoma.Semantic proximity Read ↗

Genomic landscape of extraordinary responses in metastatic breast cancer.Semantic proximity Read ↗

Exceptional Response to Olaparib and Pembrolizumab for Pancreatic Adenocarcinoma With Germline BRCA1 Mutation and High Tumor Mutation Burden: Case Report and Literature Review.Semantic proximity Read ↗

Clinical and Molecular Characteristics of Patients With Young-Onset and Average-Onset Pancreatic Adenocarcinoma.Semantic proximity Read ↗

Polygenic risk scores for autoimmune related diseases are significantly different and skewed in cancer exceptional respondersSemantic proximity Read ↗

Mining the genomes of exceptional responders.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.